Quoin Pharmaceuticals Up 28% On Plans To Start Second Trial To Evaluate QRX003 Topical Lotion

On:

Shares of Quoin Pharmaceuticals, Ltd. (QNRX) rising more than 28% Tuesday morning at $2.42.

The specialty pharmaceutical company today said it is planning to start a second clinical trial to evaluate QRX003 topical lotion in Netherton Syndrome patients.

Netherton syndrome is a rare hereditary disorder characterized by scaling skin, hair anomalies, increased susceptibility to atopic eczema.

The company said that the study will be conducted under Quoin’s currently open Investigational New Drug (IND) Application and will assess QRX003 topical lotion in Netherton patients who are currently receiving treatment including systemic therapy for symptomatic relief.

QNRX has traded in the range of $1.65-$194.62 in the last 1 year.

Source: Read Full Article

Lates News:
  1. J.B. Hunt Falls On Lower Profit In Q3, Below Street View
  2. Adobe Rises On Upbeat Earnings
  3. RXO Adds 8% In Morning Trade As Earnings Beat The Street View
  4. Bitcoin Reclaims $30K 50 Days Post Former SEC Chair's ETF Remarks
  5. Analyst Predicts 90% Likelihood of SEC Approving Bitcoin Spot ETF by January 2024 or Earlier